Episode 151: PREMIUM Aiming high and long with two studies that should impact practice

Submitted by JPM on Fri, 2012-01-06 11:09

In episode 151, James and Mike start of the new year with premium information so, by law we had to put it in a PREMIUM podcast. The first study we looked at was AIM-HIGH which showed us that we might need to re-assess how we use niacin and we finally have some reasonable data that helps us figure out how long to stay on a bisphosphonate.

Show notes

The full content of this Podcast, including the audio file, is available to Premium Members only. Click to find out the benefits of having a Premium Membership.

Why Get A Premium Membership ?

Comments

zoledronic & the BMJ

Submitted by pcat on Thu, 2012-01-12 01:17.

Both interesting studies; it's refreshing to review clinical trials which find no useful clinical benefit with a common treatment...or no better benefit with longer use. That's what Premium's all about.

I'm glad James & Mike linked to the BMJ analysis "Idolatry of the Surrogate" (Yudkin and Montori), but was crestfallen when I discovered the full-text was behind a paywall. Wish I were a hacker.

Have never ever prescribed zoledronic for anyone. Now I can start using gallons of the stuff...but only for 3 years. And not in postmenopausal men.

Paul

Thanks

Submitted by JPM on Mon, 2012-01-16 16:55.

Hi Paul - glad you found the studies useful - PREMIUM unfortunately tpically means yet another study showing things don't work as well as we thought. This info is definitely PREMIUM for those patients on these medications. Thanks. 

Post new comment

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.